Mission Therapeutics to Attend and Present at Conferences in May 2016
CAMBRIDGE, UK – 4 May 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events:
(1) Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease conference, 4 – 6 May, Wellcome Genome Campus, Hinxton, Cambridge, UK
Michael Koslowski, Chief Medical Officer, to attend the conference
The conference will bring together world leaders in the field of translational mitochondrial medicine in an interactive program designed to engage and inspire a new generation of mitochondrial researchers, who will harness this new technology to prevent and treat these devastating diseases. The meeting attracts international delegates interested in mitochondrial diseases, working in molecular genetics, biochemistry, pathology, and clinical medicine.
(2) Bio€quity Europe, 10 – 11 May 2016, Scandic Hotel, Copenhagen, Denmark
Anker Lundemose, Chief Executive Officer, to present on Tuesday 10th May at 4.00 pm CET
David Luther, Chief Financial Officer, to attend the conference
Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended the event last year.
(3) EMBO Conferences Cellular signalling and Cancer therapy, 27 – 31 May 2016, Hotel Croatia Cavtat, Dubrovnik, Croatia
The EMBO Conference brings together leading experts from different scientific disciplines to discuss new findings and future challenges in cancer research. The aim of this edition is to share new insights in our understanding of cancer and discuss how these insights provide new strategies for the development and improvement of diagnostic tools and cancer treatment.
For further events, please visit the MISSION Therapeutics website.
For more information, contact:
MISSION Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199
Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Email: missiontherapeutics@humebrophy.com
Tel: +44 (0) 20 7862 6390
NOTES TO EDITORS:
About MISSION Therapeutics
MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.
MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.
MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge
